Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Fineline Cube Aug 4, 2026
Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Fineline Cube Aug 4, 2026
Company Drug

Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China

Fineline Cube Sep 14, 2023

Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...

Policy / Regulatory

NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds

Fineline Cube Sep 14, 2023

The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...

Company Drug

MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies

Fineline Cube Sep 13, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...

Company Deals

Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline

Fineline Cube Sep 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...

Company Deals

Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine

Fineline Cube Sep 13, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...

Company Drug

Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...

Company Drug

AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial

Fineline Cube Sep 13, 2023

AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...

Company Deals

Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion

Fineline Cube Sep 13, 2023

China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...

Policy / Regulatory

NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time

Fineline Cube Sep 13, 2023

The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...

Company Medical Device

Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review

Fineline Cube Sep 13, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4

Fineline Cube Sep 13, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...

Company Drug

Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment

Fineline Cube Sep 13, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development

Fineline Cube Sep 13, 2023

China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...

Company Deals

Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO

Fineline Cube Sep 13, 2023

Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...

Company Deals

Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091

Fineline Cube Sep 13, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...

Company Medical Device

Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring

Fineline Cube Sep 13, 2023

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...

Company Drug

Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China

Fineline Cube Sep 12, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...

Company Drug

HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China

Fineline Cube Sep 12, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...

Company Drug

Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA

Fineline Cube Sep 12, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Posts pagination

1 … 510 511 512 … 702

Recent updates

  • Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership
  • Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits
  • Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer
  • Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
  • Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Company Medical Device

Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits

Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.